Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines

An inhibitory, B-cell technology, applied in the field of preparation of B-cell CD22 extracellular inhibitory peptide B2285 vaccine, can solve the problems of short action time, frequent administration, and difficulty in promotion, and achieve low production cost and high safety , less toxic side effects

Inactive Publication Date: 2010-12-01
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the existing research on the treatment of SLE, although the anti-CD22 monoclonal antibody Epratuzunab has shown the effect of inhibiting B cell function, due to its short action time, frequent adminis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines
  • Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines
  • Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1 Screening of B cell mCD22 extracellular inhibitory peptide B2285 and its therapeutic observation on ANT-induced immune dilated cardiomyopathy:

[0049] Screening of B cell mCD22 extracellular inhibitory peptides of the present invention and their effects on ANT-induced immune dilated cardiomyopathy mice

[0050] 1. Materials and methods

[0051] 1.1 Experimental animals

[0052] Select 40 inbred BALB / c mice, male, 6 weeks old, weighing about 16 grams, purchased from the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. All experimental animals were kept in the clean animal room of the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology.

[0053] 1.2 Preparation of B cell mCD22 extracellular peptide antigen vaccine

[0054] 1.2.1 Design of B cell mCD22 extracellular peptide

[0055] The amino acid sequence of the specific molecule CD22 on the surface of mouse ...

Embodiment 2

[0123] Example 2 The therapeutic observation of B cell mCD22 extracellular inhibitory peptide B2285 on spontaneous MRL / lpr lupus mice mainly mediated by B cells:

[0124] In vitro experiment of the present invention

[0125] 1. Materials and Methods

[0126] 1.1 Experimental animals

[0127] Select 6 SPF-grade MRL / lpr female lupus mice, 11-12 weeks old, weighing 36-40g, provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences; select SPF-grade female C57BL / 6 mice that are isotype-controlled with MRL / lpr lupus mice Ten rats, 10 weeks old, weighing 30-35g, were provided by the Experimental Animal Center of Wuhan University School of Medicine. All experimental animals were kept in the clean animal room of the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology.

[0128] 1.2 Preparation of B2285 antigen vaccine

[0129] The method is the same as before.

[0130] 1.3 Preparation and extraction of ant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a preparation method for B cell CD 22 extracellular peptide fragment B2285 vaccines. Sequential eight amino acids from the 85th to the 93rd starting at an amino terminal in a mice CD 22 molecule amino acid sequence, specifically in a sequence of Lys- Thr- Glu- Lys- Asp-Pro- Glu- Ser- Glu, are selected. The sequence is similar to the sequence of Lys- Asp- Gly- Lys- Val- Pro-Ser- Glu, having the sequential eight amino acids from the 81st to the 88th starting at the amino terminal in a human CD 22 molecular amino acid sequence, is located at the same functional region in a spatial structure, and has high homology. A prepared vaccine or a drug composite containing B2285 has the functions of inhibiting B cell proliferation, activating and generating antibody per se, canbe applicable to treating immunologic diseases involved or mediated B cells such as dilated cardiomyopathy testing positive in an anti-myocardial antibody, systemic lupus erythematosus with a positive antibody per se, and the like.

Description

technical field [0001] The invention belongs to the field of biotechnological medicine and biotherapeutics, and relates to a mouse B cell surface characteristic molecule CD22 (mCD22) extracellular peptide B2285 which has the effect of inhibiting B cells. The vaccine or pharmaceutical composition prepared by using B2285 can be used for Treatment of immune diseases in which B cells are involved or mainly mediated, especially immune cardiomyopathy with positive anti-myocardial antibodies and systemic lupus erythematosus with positive autoantibodies. Background technique [0002] Autoimmune diseases are caused by autoimmune disorders. The current treatment is mainly symptomatic and the application of immunosuppressants to relieve symptoms, and there is no specific and safe treatment method. Abnormal activation of B lymphocytes and the generation of pathogenic autoantibodies are one of the important characteristics of autoimmune diseases. Targeting B cells to treat diseases mainl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K39/385C07K7/06A61P37/02A61P9/00
Inventor 廖玉华袁璟余淼曹爱林林琼雯张丽华王敏
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap